|
Thyroid Dysgenesis
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Molecular Analysis of Congenital Hypothyroidism in Saudi Arabia: SLC26A7 Mutation Is a Novel Defect in Thyroid Dyshormonogenesis.
|
29546359 |
2018 |
|
Thyroid Dysgenesis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We identified the novel missense mutations p.S148F, p.R114Q and p.L177W in the BOREALIN gene in TD-affected families.
|
28025328 |
2017 |
|
Congenital Hypothyroidism
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Molecular Analysis of Congenital Hypothyroidism in Saudi Arabia: SLC26A7 Mutation Is a Novel Defect in Thyroid Dyshormonogenesis.
|
29546359 |
2018 |
|
Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
All of these suggest that CDCA8 is a key mediator of estrogen-stimulated breast cancer cell growth and survival, which can be utilized as a novel target in breast cancer treatment.
|
30953709 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer.
|
31281726 |
2019 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Cell division cycle associated 8 (CDCA8) is a putative oncogene that is upregulated in multiple types of cancer.
|
30431060 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
All of these suggest that CDCA8 is a key mediator of estrogen-stimulated breast cancer cell growth and survival, which can be utilized as a novel target in breast cancer treatment.
|
30953709 |
2019 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Cell Division Cycle Associated 8 Is a Key Regulator of Tamoxifen Resistance in Breast Cancer.
|
31281726 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Cell division cycle associated 8 (CDCA8) is a putative oncogene that is upregulated in multiple types of cancer.
|
30431060 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings suggested CDCA3, CDCA5, and CDCA8 could have a high potency as targeted breast cancer therapies.
|
29467944 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Higher expression of CDCA8 predicted poor cancer-specific survival (P < .0001, HR = 0.2752, 95% CI:0.1364-0.5554) and overall survival (P < .0001, HR = 0.4270, 95% CI: 0.2630-0.6930) in patients with BC.
|
30142792 |
2018 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings suggested CDCA3, CDCA5, and CDCA8 could have a high potency as targeted breast cancer therapies.
|
29467944 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Higher expression of CDCA8 predicted poor cancer-specific survival (P < .0001, HR = 0.2752, 95% CI:0.1364-0.5554) and overall survival (P < .0001, HR = 0.4270, 95% CI: 0.2630-0.6930) in patients with BC.
|
30142792 |
2018 |
|
Malignant Neoplasms
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Reporter gene assays revealed that the CDCA8 promoter was activated in hESCs and cancer cell lines.
|
26170459 |
2015 |
|
Primary malignant neoplasm
|
0.030 |
PosttranslationalModification
|
group |
BEFREE |
Reporter gene assays revealed that the CDCA8 promoter was activated in hESCs and cancer cell lines.
|
26170459 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In vivo anti-S180 tumor pharmacodynamics experiments showed that mice in the BOR-SA group had higher tumor inhibition rate, higher body weight and lower immune organ toxicity compared with the control group.
|
31686241 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Cell division cycle associated 8 (CDCA8) overexpression is detected in various malignant tumors and closely associated with tumor growth.
|
30142792 |
2018 |
|
Branchio-Oto-Renal Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This mapping led us to reevaluate the localization of the gene responsible for BOR syndrome and has now focused the search for the BOR gene to within the limits of this deletion.
|
8786145 |
1996 |
|
Branchio-Oto-Renal Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Detection of a megabase deletion in a patient with branchio-oto-renal syndrome (BOR) and tricho-rhino-phalangeal syndrome (TRPS): implications for mapping and cloning the BOR gene.
|
8824802 |
1996 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that CDCA8 was overexpressed in cutaneous melanoma tissues and cells lines compared with normal tissues, and high expression of CDCA8 was significantly associated with poorer prognosis in patients with cutaneous melanoma.
|
30431060 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The present study aimed to examine the role of CDCA8 in cutaneous melanoma, with a focus on the association of its expression to prognosis and metastasis.
|
30431060 |
2019 |
|
Cutaneous Melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that CDCA8 was overexpressed in cutaneous melanoma tissues and cells lines compared with normal tissues, and high expression of CDCA8 was significantly associated with poorer prognosis in patients with cutaneous melanoma.
|
30431060 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
CENPA, KIF20A and CDCA8 might promote the tumorigenesis and progression of PCa, especially in BCR and metastasis, which could be novel therapeutic targets and biomarkers for diagnosis, prognosis of PCa.
|
31031850 |
2019 |